New Delhi, July 24 -- US-India Strategic Partnership Forum (USISPF) President and CEO Mukesh Aghi on Friday said that higher tariffs proposed on Indian generic medicines will ultimately end up inflating healthcare costs for the United States government itself.

Speaking to ANI, Aghi highlighted that India supplies nearly 40 per cent of all generic drugs consumed in the United States, many of which are directly procured through government-funded healthcare programs like Medicare and Medicaid to significantly cut public healthcare expenditure.

Commenting on US President Donald Trump's announcement of future tariff hikes on generic pharmaceutical imports, Aghi noted that it is too early to react since the steep increases are slated to take ...